Becaplermin
| Clinical data | |
|---|---|
| Trade names | Regranex |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a699049 |
| Pregnancy category |
|
| Routes of administration | Topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
  (what is this?) (verify) | |
Becaplermin (brand name Regranex) is a cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers. [1]
Use for diabetic foot ulcers has been described.[2] Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster.[3] Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care.[4]
The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator. [5]
It is also known as "platelet-derived growth factor BB".[6] Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. [7]
Boxed warning has been added to the safety label to describe an increase rate of death from cancer when three or more tubes are used.[8] Regranex should be used with caution in patients with known malignancy.[9]
References
- ^ http://www.regranex.com/patient/pdf/PI_full_version.pdf.
- ^ Nagai MK, Embil JM (February 2002). "Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers". Expert Opin Biol Ther. 2 (2): 211–8. doi:10.1517/14712598.2.2.211. PMID 11849120.
- ^ Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21:822-827.
- ^ Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg. 2002;19:483-491. Persson U, Willis M, Odegaard K, Apelqvist J. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health. 2000;3 Suppl 1:39-46.
- ^ http://www.regranex.com/patient/pdf/PI_full_version.pdf
- ^ becaplermin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- ^ Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
- ^ Medscape Article
- ^ http://www.regranex.com/patient/pdf/PI_full_version.pdf
External links
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
 | This dermatologic drug article is a stub. You can help Wikipedia by expanding it. |